These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 29540589)

  • 21. Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    Weeda MM; van Nederpelt DR; Twisk JWR; Brouwer I; Kuijer JPA; van Dam M; Hulst HE; Killestein J; Barkhof F; Vrenken H; Pouwels PJW
    J Neurol; 2024 Jan; 271(1):355-373. PubMed ID: 37716917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Automated segmentation of cerebral deep gray matter from MRI scans: effect of field strength on sensitivity and reliability.
    Chu R; Hurwitz S; Tauhid S; Bakshi R
    BMC Neurol; 2017 Sep; 17(1):172. PubMed ID: 28874119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability.
    Magon S; Chakravarty MM; Amann M; Weier K; Naegelin Y; Andelova M; Radue EW; Stippich C; Lerch JP; Kappos L; Sprenger T
    Hum Brain Mapp; 2014 Aug; 35(8):4193-203. PubMed ID: 24510715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
    Kappos L; Radue EW; Chin P; Ritter S; Tomic D; Lublin F
    J Neurol; 2016 Feb; 263(2):354-360. PubMed ID: 26645392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
    Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
    Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
    PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.
    Kalinin I; Makshakov G; Evdoshenko E
    AJNR Am J Neuroradiol; 2020 May; 41(5):804-808. PubMed ID: 32381540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis.
    Fisher E; Nakamura K; Lee JC; You X; Sperling B; Rudick RA
    Mult Scler; 2016 Apr; 22(5):668-76. PubMed ID: 26238463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.
    Bergsland N; Zivadinov R; Dwyer MG; Weinstock-Guttman B; Benedict RH
    Mult Scler; 2016 Sep; 22(10):1327-36. PubMed ID: 26541795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI.
    Battaglini M; Jenkinson M; De Stefano N;
    Hum Brain Mapp; 2018 Mar; 39(3):1063-1077. PubMed ID: 29222814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fingolimod effect on brain volume loss independently contributes to its effect on disability.
    Sormani MP; De Stefano N; Francis G; Sprenger T; Chin P; Radue EW; Kappos L
    Mult Scler; 2015 Jun; 21(7):916-24. PubMed ID: 25662353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year Study.
    Preziosa P; Storelli L; Meani A; Moiola L; Rodegher M; Filippi M; Rocca MA
    Neurotherapeutics; 2021 Apr; 18(2):878-888. PubMed ID: 33483938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).
    Amann M; Andělová M; Pfister A; Mueller-Lenke N; Traud S; Reinhardt J; Magon S; Bendfeldt K; Kappos L; Radue EW; Stippich C; Sprenger T
    Neuroimage Clin; 2015; 7():43-52. PubMed ID: 25610766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subtyping relapsing-remitting multiple sclerosis using structural MRI.
    Zhuo Z; Li Y; Duan Y; Cao G; Zheng F; Ding J; Tian D; Wang X; Wang J; Zhang X; Li K; Zhou F; Huang M; Li Y; Li H; Zeng C; Zhang N; Sun J; Yu C; Han X; Haller S; Barkhof F; Shi F; Liu Y
    J Neurol; 2021 May; 268(5):1808-1817. PubMed ID: 33387013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Hyun JW; Park G; Kwak K; Jo HJ; Joung A; Kim JH; Lee SH; Kim S; Lee JM; Kim SH; Kim HJ
    Eur J Neurol; 2017 Feb; 24(2):437-445. PubMed ID: 28009104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
    Conway DS; Planchon SM; Oh SH; Nakamura K; Thompson NR; Sakaie K; Ontaneda D
    Mult Scler Relat Disord; 2021 Jan; 47():102635. PubMed ID: 33260053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
    Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time course of lesion-induced atrophy in multiple sclerosis.
    Carolus K; Fuchs TA; Bergsland N; Ramasamy D; Tran H; Uher T; Horakova D; Vaneckova M; Havrdova E; Benedict RHB; Zivadinov R; Dwyer MG
    J Neurol; 2022 Aug; 269(8):4478-4487. PubMed ID: 35394170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.